Compare IONQ Inc (IONQ) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

IONQ trades at $34.73, down 4.25% today, with a bearish technical signal despite bullish oscillators. The company shows strong revenue growth (2025: $130M, 2026: $246M) but deep losses (2025: -$510M, 2026: -$1.4B), resulting in negative margins. Analyst consensus is bullish with a $65.20 price target (66.7% Buy ratings), supported by recent positive coverage from Bank of America and media optimism around quantum computing prospects.

Outlook: High growth potential in quantum computing with institutional backing, but profitability remains distant. Risks include cash burn, execution challenges, and rich valuations (P/S: 43.6). Investors must weigh long-term disruption potential against near-term financial strain.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.